United States · FDA National Drug Code directory

Ondansetron

A source-listed medicine record.

Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.

Medicine identity

Source reference
68071-4115_4ef6e0dd-a995-22cf-e063-6394a90add4f
Product NDC
68071-4115
Form
TABLET, ORALLY DISINTEGRATING
Composition / generic term
Ondansetron
Labeler
NuCare Pharmaceuticals,Inc.
Marketing category
ANDA
Marketing start / end (source format)
20070627
Source listing expiry
20271231

Source-listed ingredients

  • ONDANSETRON — 4 mg/1

These values do not establish equivalence or a dose recommendation.

Packages

  • 2 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (68071-4115-2) · 68071-4115-2
  • 3 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (68071-4115-3) · 68071-4115-3
  • 4 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (68071-4115-4) · 68071-4115-4

Source and coverage

Open FDA National Drug Code directory

Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.

Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.

Browse United States records →